sur ONCODESIGN PRECISION MEDICINE S.A. (isin : FR001400CM63)
OPM-101 Phase 1 Trial Results Presented at UEG Week 2024
Oncodesign Precision Medicine (OPM), a biopharmaceutical company specializing in precision medicine, announced the presentation of its drug candidate OPM-101 at the United European Gastroenterology (UEG) Week 2024 in Vienna. The presentation was delivered by Professor Laurent Peyrin-Biroulet and Bruno Robin, highlighting safety and pharmacological data from a Phase 1 trial involving healthy volunteers.
Professor Peyrin-Biroulet emphasized the potential of OPM-101 as an oral treatment for Chronic Inflammatory Bowel Disease (CIBD), specifically targeting ulcerative colitis. The Phase 1 trial demonstrated a strong safety profile and high target engagement, positioning OPM-101 as a promising therapeutic approach.
The presentation, part of a session on novel therapeutic approaches, underscores the progress in OPM's clinical program focusing on resistant and metastatic cancers. The company plans to initiate Phase Ib/IIa trials for OPM-101 by the end of 2024.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ONCODESIGN PRECISION MEDICINE S.A.